AlphaCrest Capital Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-33,648
| Closed | -$706K | – | 347 |
|
|
2022
Q3 | $706K | Buy |
33,648
+22,807
| +210% | +$479K | 0.04% | 811 |
|
|
2022
Q2 | $337K | Sell |
10,841
-25,047
| -70% | -$779K | 0.02% | 1079 |
|
|
2022
Q1 | $1.47M | Buy |
+35,888
| New | +$1.47M | 0.08% | 369 |
|
|
2021
Q4 | – | Sell |
-4,563
| Closed | -$228K | – | 1383 |
|
|
2021
Q3 | $228K | Buy |
4,563
+580
| +15% | +$29K | 0.01% | 1187 |
|
|
2021
Q2 | $251K | Sell |
3,983
-5,606
| -58% | -$353K | 0.01% | 1153 |
|
|
2021
Q1 | $891K | Buy |
9,589
+4,197
| +78% | +$390K | 0.05% | 547 |
|
|
2020
Q4 | $483K | Buy |
5,392
+3,163
| +142% | +$283K | 0.04% | 668 |
|
|
2020
Q3 | $230K | Buy |
+2,229
| New | +$230K | 0.03% | 989 |
|
|
2020
Q2 | – | Sell |
-7,535
| Closed | -$436K | – | 957 |
|
|
2020
Q1 | $436K | Buy |
+7,535
| New | +$436K | 0.05% | 629 |
|